Compare · ABMD vs SYK
ABMD vs SYK
Side-by-side comparison of ABIOMED Inc. (ABMD) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABMD and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $113.09B, about 9.0x ABMD ($12.61B).
- SYK has hit the wire 10 times in the past 4 weeks while ABMD has been quiet.
- SYK has more recent analyst coverage (25 ratings vs 9 for ABMD).
- Company
- ABIOMED Inc.
- Stryker Corporation
- Price
- $381.11+0.07%
- $295.17+0.58%
- Market cap
- $12.61B
- $113.09B
- 1M return
- -
- +1.42%
- 1Y return
- -
- -22.90%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 10
- Recent ratings
- 9
- 25
ABIOMED Inc.
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest ABMD
- Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical
- SEC Form SC 13G/A filed by ABIOMED Inc. (Amendment)
- SEC Form 15-12G filed by ABIOMED Inc.
- SEC Form SC 13G filed by ABIOMED Inc.
- SEC Form 4: Sutter Martin P returned 123,370 shares to the company, closing all direct ownership in the company
- SEC Form 4: Puhy Dorothy E returned 14,590 shares to the company, closing all direct ownership in the company
- SEC Form 4: Trapp Todd A returned 14,166 shares to the company, closing all direct ownership in the company
- SEC Form 4: Plano Matthew T. returned 8,406 units of Common Stock $.01 par value to the company, closing all direct ownership in the company
- SEC Form 4: Minogue Michael R returned 410,632 units of Common Stock $.01 par value to the company, closing all direct ownership in the company
- SEC Form 4: Greenfield Andrew J returned 23,484 shares to the company, closing all direct ownership in the company
Latest SYK
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation